20:42 , Oct 31, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 30 genomic loci could help predict the risk of schizophrenia. Genome-wide association studies in 47,559 schizophrenia patients and 70,936 healthy volunteers identified associations between the disease and SNPs on 30 loci, including...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-31 (miR-31); neuronal nitric oxide synthase 1 (NOS1; nNOS)

Cardiovascular disease INDICATION: Fibrillation Cell culture and goat studies suggest inhibiting miR-31 could help treat atrial fibrillation (AF). miR-31 levels were higher in atrial myocytes from AF patients and in the left ventricle of a goat model...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Inducible nitric oxide synthase 2 (NOS2; iNOS); epidermal growth factor receptor variant III (EGFRvIII) In...
07:00 , Oct 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neuronal nitric oxide synthase 1 (NOS1; nNOS) Rat and tissue culture studies identified 3,6-disubstituted indole derivative-based...
08:00 , Dec 9, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Discs large homolog 4 (DLG4; PSD95); neuronal nitric oxide synthase 1 (NOS1; nNOS) Rodent studies suggest...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

NXN-188: Phase II data

The double-blind, U.S. Phase II Study 204 trial in 174 patients with moderate to severe acute migraine headache without aura showed that a single dose of oral 600 mg NXN-188 missed the primary endpoint of...
08:00 , Mar 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Musculoskeletal disease ...
08:00 , Nov 6, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology ...
07:00 , Mar 27, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...
08:00 , Nov 19, 2007 |  BioCentury  |  Emerging Company Profile

NeurAxon: No NO pain

While the triptan class of marketed migraine drugs are effective, they are associated with cardiovascular side effects and do not address the development of central hypersensitivity common in migraine patients, which may limit the drugs'...